Virtu Financial’s ALX Oncology ALXO Stock Holding History

Virtu Financial’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,702	Closed	-$15K	–	1589
2025 Q4	$15K	Buy	+13,702	New	+$20.7K	﹤0.01%	1465

Other funds holding ALXO

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Virtu Financial's ALXO Position: Q1 2026 in Review

Virtu Financial sold out of ALX Oncology (ALXO) in Q1 2026, closing a stake of 13,702 shares — an estimated $15K sold.

Virtu Financial first reported a position in ALXO in Q4 2025 and held it in 1 quarter. The position peaked at $15K in Q4 2025. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

Virtu Financial reported no remaining ALX Oncology position as of Q1 2026 after selling out during the quarter.
Virtu Financial sold 13,702 ALX Oncology shares in Q1 2026, an estimated $15K.
Virtu Financial first reported a position in ALX Oncology in Q4 2025 and held it in 1 quarter.
Virtu Financial's ALX Oncology position peaked at $15K in Q4 2025.
69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.